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Abstract
Objective: GH and IGFs have mitogenic properties, causing speculation that GH treatment could
increase risk of malignancy. While studies in GH-treated childhood cancer survivors have suggested a
slight increase in second neoplasms, studies in GH-treated adults have been equivocal.
Design: Incidence of de novo and second cancers was evaluated in 6840 GH-treated and 940
non GH-treated adult patients in the Hypopituitary Control and Complications Study pharmacoepi-
demiological database.
Methods: Evident cancer cases were evaluated in the main analysis, with sensitivity analyses including
probable and possible cancers. Standardized incidence ratios (SIRs) for cancers were calculated using
Surveillance, Epidemiology and End Results for the USA and GLOBOCAN for all other countries.
Results: During the mean follow-up of 3.7 years/GH-treated patient, 142 evident cancer cases were
identiﬁed, giving an overall SIR of 0.88 (95% conﬁdence interval (CI) 0.74–1.04); 95% CIs included
the value of 1.0 for each country examined. The SIR for GH-treated patients from the USA (71 cases)
was 0.94 (95% CI 0.73–1.18), and for non GH-treated patients from the USA (27 cases) was 1.16
(95% CI 0.76–1.69). For GH-treated patients from the USA aged !35 years, the SIR (six cases) was
3.79 (1.39–8.26), with SIR not elevated for all other age categories; SIR for patients from the USAwith
childhood onset (CO) GH deﬁciency (GHD) was 2.74 (95% CI 1.18–5.41). The SIR for colorectal cancer
in GH-treated patients (11 cases) was 0.60 (95% CI 0.30–1.08).
Conclusions: With relatively short follow-up, the overall primarycancer risk in 6840 patients receiving
GH as adults was not increased. Elevated SIRs were found for subgroups in the USA cohort deﬁned by
age !35 years or CO GHD.
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Introduction
A risk of malignancies has been speculated in
GH-treated patients, based on the mitogenic and
proliferative properties of GH and insulin-like growth
factors (IGFs), demonstrated by both experimental and
epidemiological analyses (1–5). Previous surveillance
data from the Hypopituitary Control and Complications
Study (HypoCCS) and the Kabi International Metabolic
Surveillance (KIMS) study have suggested that adult
GH replacement is safe (6, 7). However, a potential
association between GH treatment of children and
adults and an increased risk for malignancy has
remained an important topic of debate.
Earlier studies suggested that GH treatment was not
associated with increased tumor recurrence or second
neoplasms (8–12). However, data from the 5-year
survivors of childhood cancer enrolled in the Childhood
Cancer Survivor Study indicated an increased, though
low, risk of second neoplasms in GH-treated childhood
cancer survivors compared with non GH-treated cancer
survivors (13, 14). The relative risk (95% conﬁdence
interval (CI)) of second neoplasm for GH-treated versus
non GH-treated patients was 2.15 (1.3–3.5), with
meningiomas being the most common second neo-
plasm in GH-treated patients (14). Some studies of
non GH-treated hypopituitary adults have suggested an
increased cancer risk (15–17), but others have not (18),
whereas for GH-treated cohorts, the results have been
equally variable (17, 19–21). Swerdlow et al. (19) found
that the overall cancer risk in 1849 British adults who
received pituitary-derived GH as a child or young adult
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general population, but the occurrence of colorectal
cancer was elevated, with a standardized incidence ratio
(SIR; 95% CI) of 7.9 (1.0–28.7) based on two cases. A
large retrospective study in 6107 adults from the USA
treated in childhood with pituitary-derived GH reported
no increased mortality from de novo tumors, colon
cancer, or Hodgkin lymphoma (20), and a prospective
study of 289 GH-treated Swedish hypopituitary patients
indicated no increased risk for overall or colorectal
cancer (17).
We undertook this study to determine the risk of
cancer in a large cohort of adult GH-deﬁcient patients
enrolled in HypoCCS, a prospective, international
observational study. To our knowledge, this is the ﬁrst
reported prospective evaluation of the risk of primary
cancer in a large cohort of adult patients receiving GH
therapy during adulthood for GH deﬁciency (GHD).
Methods
Study design and study population
The primary objective of HypoCCS is to determine long-
term safety of GH replacement (Humatrope; Eli Lilly
and Company, Indianapolis, IN, USA) in adults with
GHD (7, 22). All patients had established diagnoses of
adult GHD, either alone or with other pituitary
hormone deﬁciencies, determined by clinical history
and/or biochemical testing. As HypoCCS is a non-
interventional study, the diagnostic approach and
treatment decisions were determined by the investi-
gating physician but should be made in accordance
with the Humatrope package insert for that country.
Patients were ineligible for HypoCCS if they had
unresolved or unstable conditions, listed as contra-
indications or precautions for GH therapy, including
evidence or suspicion of active malignancy or evidence
of ongoing pituitaryor other intracranial tumor activity.
HypoCCS is conducted in accordance with the
Declaration of Helsinki guidelines and all applicable
regulatory requirements in the participating countries.
Ethical review board approval and written consent from
all patients for data collection, electronic processing,
and publication were obtained in accordance with the
national laws. HypoCCS is registered with Clinical-
Trials.gov, number NCT 01088399. The patients for
this analysis were recruited from Austria, Belgium,
Canada, Czech Republic, Denmark, France, Germany,
Hungary, Iceland, Italy, Norway, Spain, Sweden, the
Netherlands, the UK, and the USA.
Between 1996 and July 2008 (the cutoff date for
this analysis), the HypoCCS database included 7785
patients with at least one follow-up visit; 6840 were
GH-treated during HypoCCS participation, 940
were non GH-treated, and ﬁve had unknown treat-
ment status (excluded from analysis). Of the 6840
GH-treated patients, 5522 (81%) were reported to
have adult onset (AO) GHD and 1299 (19%) child-
hood onset (CO) GHD.
Follow-up time was calculated per patient from date
of ﬁrst visit in HypoCCS until the date of the last
available follow-up visit, date of completion of the study,
date of the reported cancer, or date of death, whichever
was the latest occurrence. It should be noted that the
ﬁrst HypoCCS visit date may not have reﬂected the exact
start of GH treatment.
Primary cancer case selection
Preliminary review for potential cancer cases
HypoCCS collects data on adverse events, whether
they are considered GH related by participating
investigators. All adverse events in the database were
coded using the Medical Dictionary for Regulatory
Activities (MedDRA) version 10.0 (http://www.med-
dramsso.com (accessed 26 November 2010)). The
HypoCCS database was systematically reviewed using
the Malignancies Standardized MedDRA Query (SMQ)
to select events potentially related to malignant disease.
The ‘Malignancies SMQ’ is a surveillance tool
containing categories of events that only indicates the
possibilityof cancer; thus, the preliminary list contained
many non-cancers and related conditions/therapies, as
well as recurrences of previous malignancies. Where
a d v e r s ee v e n tt e r m sw e r ev a g u eo rr e l a t e dt o
procedures, requests for clariﬁcation were sent to
participating investigators.
HypoCCS also prospectively collects information on
new neoplastic conditions, using speciﬁc checkboxes on
the case report forms. Such entries were reviewed to
includeanypotentialcasesnotreportedasadverseevents.
Inaddition,seriousadverseevent(SAE)reportsintheLilly
pharmacovigilance database were included if not already
present in the preliminary listing. SAE reports were
reviewed for all cases where death was reported.
Selection of incident cancer cases Only incident
invasive cancer events (primary site only) diagnosed
after thedateofenrollmentinHypoCCSwereincludedin
this analysis. Potential cancer cases were categorized as
de novo (included), second (included), and recurrence
(excluded). De novowas deﬁned as the ﬁrst occurrence of
neoplasm in a patient with no history of neoplasm, and
second as development, by an independent oncogenic
event, of a different neoplasm type in a patient with a
previous neoplasm. The list of potential incident cases
wasreviewedbythreeauthors(WWW,DMG,andLLR)
who independently scored cases, as follows: 1, evident
cancer case; 2, high indexof suspicion for a cancer case;
3, moderate index of suspicion for a cancer case; 4,
highly unlikely to reﬂect a cancer case; and 5, not a
cancercase.Eventsrecordedasproceduresorlaboratory
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according to the classiﬁcation. Individual scores were
averaged; where any individual score differed by two or
more from other reviewers, the case was discussed and
consensus reached. Cases with an average score of 1.0
were deﬁned as ‘evident cancer cases’ for the main
analysis. Sensitivityanalyses were performed to account
for non-speciﬁc event terms (mass, lesion, lump, and
tumor), procedures (elevated prostate speciﬁc antigen
(PSA), abnormal pap smear, and breast biopsy), and
investigationsrecordedwithoutsupportinginformation;
cases with an average score of !2.5 were deﬁned as
‘probable cancer cases’ for ‘sensitivity analysis level 1’
and thosewithanaveragescoreof!3.5were deﬁned as
‘possible cancer cases’ for ‘sensitivityanalysis level 2’. In
the eventof adeath where noinvolvementofcancer was
indicated, but cause could not be conﬁrmed (20 cases
through the course of the study since 1996, including
eight with presumed or likely morbidity provided by the
investigator), the case was not included in the main or
sensitivityanalyses, but the follow-up time was included
in total patient-years.
SIR and 95% CI calculations
SIRs were calculated, by country, for both primary all-
sites cancer and colorectal cancer, as the ratio between
the number of cases observed in HypoCCS and the
expected number of incident cases based on reference
data. The expected case count was determined using
country-, gender-, and age-speciﬁc cancer incidence
rates for the general population in Europe and Canada
(23), and gender-, race-, age-,and calendar year-speciﬁc
cancer incidence rates for the general population in the
USA (24), utilizing the corresponding number of
patient-years in HypoCCS. Total observed and expected
counts were obtained by sum of the strata. An estimate
of total SIRwas calculated using the pooled results from
Europe/Canada and the USA.
Incidence rates for invasive cancers are available for
all the participating countries in the GLOBOCAN data
published by the International Agency for Research on
Cancer (IARC (23)). GLOBOCAN 2002 was selected as
the best reference because this represented the midpoint
of the period of HypoCCS data collection. The USA
contributed approximately half of the enrolled HypoCCS
patients, and national incidence rates were available
from the Surveillance, Epidemiology and End Results
(SEER) program (24). Cancer cases in HypoCCS were
deﬁned according to the criteria of SEER (24), and thus
excluded non-melanoma skin cancer and in-situ cancer
except breast or bladder. While recognizing that in-situ
breast and bladder cancers are not included in the
GLOBOCAN registries (23), they were included in our
analysis to provide a conservative assessment.
The observed number of cancer cases was assumed to
follow a Poisson distribution, and 95% CIs were
calculated using an exact method (25).
Results
Demographic factors at the start of GH therapy and
details of GH treatment are provided in Table 1, for both
GH-treated and non GH-treated patients from all
countries. The meanGS.D. follow-up/patient for all
countries was 3.7G2.9 years for GH-treated and
2.9G2.4 years for non GH-treated patients, while for
patients from the USA, it was 3.3G2.6 and 3.0G2.7
years respectively.
Following the case identiﬁcation process, 142 cases
in 138 GH-treated patients and 33 cases in 32
non GH-treated patients were included in the main
analysis, with 176 cases in 172 GH-treated and 37
cases in 36 non GH-treated patients in the sensitivity
analyses (Fig. 1). The most common cancer diagnoses
from GH-treated patients in the main analysis were
prostate cancer (nZ24), breast cancer (nZ16), malig-
nant melanoma (nZ15, including one case of lentigo
maligna), colorectal cancer (nZ11), lung cancer
(nZ11), thyroid cancer (nZ9), and glioma (nZ9,
including speciﬁed cases of astrocytoma and glioblas-
toma multiforme).
Of the 138 GH-treated patients with cancer cases
included in the main analysis, 85 were male and 21 had
a report of previous malignant disease (Table 2). Of the
previous primary cancers, eight were intracranial
tumors (astrocytoma, medulloblastoma, and dysgermi-
noma) or leukemia, of the type often occurring during
Table 1 Demographic and diagnostic factors at study entry and GH






Male 3571 (52%) 549 (58%)
Female 3269 (48%) 391 (42%)
GH deﬁciency onset
a
Adult (AO) 5522 (81%) 813 (86%)
Childhood (CO) 1299 (19%) 127 (14%)
Cause of GH deﬁciency
Pituitary adenoma 45% 54%
Craniopharyngioma 11% 9%
Other intracranial tumor 7% 9%
Idiopathic 17% 9%
Other diagnoses 20% 19%






Median age at study
entry (years; Q1, Q3)
46.4 (34.1, 56.3) 54.4 (42.2, 65.6)
Median starting GH dose
(mg/day; Q1, Q3)
0.30 (0.20, 0.46) NA
MeanGS.D. follow-up





a19 GH-treated patients, where onset of GHD was unknown.
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onset of the second cancer of 30.6G11.2 years. The
remaining 13 patients, with average age at onset of
secondcancerof68.0G10.1years,hadprimarycancers
more typically associated with adulthood, including six
patients with skin cancers and single cases of breast,
cervical, lung, nasal, nasopharyngeal, and thyroid
cancers, plus hemangiopericytoma (Table 2).
The SIRs for all primary invasive cancers in HypoCCS
are shown by country when expected case count
exceeds ﬁve and total in Table 3. The overall estimated
SIR for evident cases (main analysis) was 0.88 (95% CI
0.74–1.04). The SIR for cancers in GH-treated patients
from the USA was 0.94 (95% CI 0.73–1.18).
The only country with sufﬁcient patients for
calculation of SIR in non GH-treated patients was the
USA (Table 4). Overlapping 95% CIs for SIR were
observed between the GH-treated and non GH-treated
groups, with the SIR for non GH-treated patients from
the USA being similar to the GH-treated value but
with wider 95% CI (SIR 1.16, 95% CI 0.76–1.69). In
addition, for the USA cohort, when age at entry into
HypoCCS for GH-treated patients was analyzed by age
quartiles (!35.0, 35.0 to !47.4, 47.4 to !57.5, and
R57.5 years), the SIR was 3.79 (95% CI 1.39–8.26)
for the lowest age group (SIR was not elevated in any
other age quartile). However, this was based on six
observed and 1.58 expected cases; four of the six
patients had CO GHD, and for ﬁve of the six patients,
the cancer was a second neoplasm following histories
of leukemia (two cases), pineal dysgerminoma, cranio-
pharyngioma, and pituitary adenoma. Also, when
considering GHD onset in patients from the USA, the
SIR was 2.74 (1.18–5.41) for CO patients (eight cases)
versus 0.86 (0.66–1.11) for AO patients (63 cases).
Other subgroup analyses for all countries at the main
analysis level did not detect potential predictive factors
in any of the following parameters: previous history of
cancer (yes versus no), gender (male versus female),
GHD onset (AO versus CO), GH therapy prior to
HypoCCS (yes versus no).





Level 1 sensitivity analysis
(probable cancer)















Figure 1 Adult hypopituitary patients reviewed for cancer case
selection and inclusion in the main, level 1 and level 2 sensitivity
analyses, according to GH treatment status as adults in the
HypoCCS study. Note i) that an individual patient could have had
more than one cancer event, with each event counted as a separate
case for the incidence analysis; ii) case and patient counts are
cumulative across analysis levels.
Table 2 Second cancers in GH-treated patients included in the main analysis.









b 31.1 AO F
Astrocytoma Thyroid cancer 25.4 CO F
Astrocytoma Uterine cancer 53.7 AO F
Medulloblastoma Glioblastoma 20.2 CO M
Medulloblastoma Papillary thyroid carcinoma 34.9 CO M
Pineal dysgerminoma Glioblastoma multiforme 31.4 CO M
Acute lymphocytic leukemia Malignant melanoma 31.4 CO F
Lymphoblastic leukemia Ewing sarcoma 16.8 CO M
Basal cell carcinoma Polycythemia vera 65.9 AO M
Basal cell carcinoma and pituitary adenoma Malignant melanoma 84.0 AO M
Basal cell carcinoma and pituitary adenoma Pancreatic islet cell cancer 69.5 AO F
Basal cell carcinoma, skin cancer, and
craniopharyngioma
Lentigo maligna 81.9 CO M
Malignant melanoma Malignant melanoma
b 57.6 AO F
Squamous cell carcinoma and pituitary adenoma Malignant melanoma 64.7 AO M
Breast cancer and pituitary adenoma Lung cancer 73.1 AO F
Cervical cancer Glioma 61.3 AO F
Hemangiopericytoma Lymphoma 67.1 AO M
Lung cancer and pituitary adenoma Colon adenocarcinoma 77.3 AO M
Maxillary sinus cancer Lung cancer 60.4 AO F
Nasopharyngeal carcinoma Malignant soft tissue tumor 47.9 AO M
Papillary thyroid cancer, meningioma Endometrial adenocarcinoma 73.5 AO F
AO, adult onset; CO, childhood onset; F, female; GHD, GH deﬁciency; M, male.
aDuring HypoCCS participation.
bPotentially recurrent cancers, but second malignancy could not be discounted.
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cannot be precisely determined for these analyses,
either in terms of contribution to total number of
cases or patient-years of exposure. However, for the
USA, the SIR for all GH-treated patients was similar to
the SIR for the GH-treated patients who were not
previously exposed to GH before studyentry. The SIR for
GH-treated patients who were GH naive at study entry
was 0.91 (0.69–1.18) based on 58 observed cases and
an expected count of 63.68 versus the SIR of 0.94
(0.73–1.18) for all GH-treated patients.
A total of 16 cases of colorectal cancer were observed
in the overall HypoCCS population (11 in the
GH-treated group and ﬁve in the non GH-treated
group), with 11 in the USA (six GH-treated and ﬁve
non GH-treated). The estimated SIR for cases in
GH-treated patients was 0.60 (0.30–1.08) versus 1.51
(0.49–3.52) for non GH-treated patients (Table 5). All
11 colorectal cancers in the GH-treated patients were
in-patients with AO GHD, all of whom were considered
naive to GH treatment at HypoCCS entry. Of the
observed 11 cases, nine were male GH-treated patients;
however, the 95% CI for the different genders showed
substantial overlap (Table 5).
Inclusion of cases where malignant status could not
be clariﬁed increased the number of observed cases from
142 to 144 (level 1 sensitivity, representing probable
cases) and 176 (level 2 sensitivity, representing possible
cases), giving SIRs of 0.89 (95% CI 0.75–1.05) and
1.09 (0.93–1.26) respectively, for all countries, and
0.96 (0.75–1.21) and 1.31 (1.06–1.59) respectively, for
patients from the USA. The 34 cases added for the
sensitivity analyses included event terms of breast
biopsy/lump/mass/neoplasm (eight cases), elevated
PSA/prostate nodule (six cases), lung lesion/neoplasm/
nodule (ﬁve cases), abnormal pap smear (four cases),
unspeciﬁed brain lesions (two cases), and renal mass
(two cases).
Discussion
Replacement therapy with GH in adults with GHD was
ﬁrst approved in 1995. Studies in childhood cancer
survivors indicated an approximate two- to three-fold
increased risk of second neoplasms, and there is a
concern that adult GH treatment could be associated
with an increased cancer risk (17, 19, 20). In contrast
to previous studies in GH-treated adults, this is the ﬁrst
reported prospective, large-scale, follow-up examining
cancer occurrence. This study indicated no increased
risk for primary cancers in GH-treated adult hypopitui-
tary patients in HypoCCS compared with general
population cancer rates, standardized by country,
gender, and age.
Our analysis included 21 patients with a previous
history of malignant disease prior to HypoCCS entry,
including eight with history of intracranial tumors or
leukemia. Analysis of cancer cases in the USA by age
quartiles indicated an increased risk for the youngest
group (!35 years), based on 1.58 expected cases and
six observed cases. The second neoplasms followed
intracranial tumors or leukemia in ﬁve of the six
cases, and four of these had CO GHD. Similarly,
analysis by GHD onset in patients from the USA,
indicated an elevated SIR for CO patients, based on
eight cases. The 95% CIs in these subgroups were
wide, with lower conﬁdence limits close to 1, and it is
reasonable to suggest that such patients may have
had a higher risk of second neoplasms, consistent with
previous reports demonstrating an increased risk
associated with survival of childhood neoplastic
disease (13, 14). Previous radiotherapy for childhood
cancer may be an important inﬂuence on the
increased cancer incidence in this group. However,
there are insufﬁcient data, regarding history, type, and
quantity of radiotherapy in the HypoCCS database, to
conduct a speciﬁc analysis to assess the risk for
radiation-associated cancer morbidity.
An increased risk for colorectal cancer (SIRZ7.9,
95% CI 1.0–28.7) was reported in adults from the UK
who received pituitary GH between 1959 and 1985
during childhood or early adulthood (19). This was
based on two cases observed versus a very small
expected count. Although the authors acknowledged
that their ﬁndings were based on a small observed case
count and that data collected on pituitary GH dosing
Table 3 Primary invasive cancer incidence by country for
GH-treated adult hypopituitary patients in HypoCCS. SIRs were
calculated for reference population cancer rates from SEER






cases SIR (95% CI)
Denmark 151 7 5.48 1.28 (0.51–2.63)
Germany 435 5 9.85 0.51 (0.16–1.18)
Italy 833 5 11.52 0.43 (0.14–1.01)
Sweden 348 15 18.87 0.79 (0.44–1.31)
The Netherlands 439 16 16.12 0.99 (0.57–1.61)
UK 462 10 11.27 0.89 (0.43–1.63)
USA 3165 71 75.79 0.94 (0.73–1.18)
Other countries
a 1007 13 12.72 1.02 (0.54–1.75)
Total 6840 142 161.63 0.88 (0.74–1.04)
CI, conﬁdence interval; SIR, standardized incidence ratio.
aSum of countries where expected case count was !5: Austria, Belgium,
Canada, Czech Republic, France, Hungary, Iceland, Norway, and Spain.
Table 4 Primary invasive cancer incidence in GH-treated and non






cases SIR (95% CI)
GH-treated (nZ3165) 71 75.79 0.94 (0.73–1.18)
Non GH-treated (nZ631) 27 23.28 1.16 (0.76–1.69)
CI, conﬁdence interval; SIR, standardized incidence ratio.
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GH regimens, further investigation of colorectal cancer
in current cohorts was justiﬁed. Speciﬁc analysis for
colorectal cancer in HypoCCS yielded 16 cases in total
from all countries. The SIRwas 0.60 (95% CI 0.3–1.08)
for the 11 cases in the GH-treated group and 1.51
(0.49–3.52) for the ﬁve cases in the non GH-treated
group. All 11 colorectal cancers in the GH-treated
group were inpatients naive to GH treatment at
HypoCCS entry and, in contrast to the population
studied previously (19), all had AO GHD.
Our study included sensitivity analyses that incor-
porated cases of uncertain malignant status. Although
the analyses were deliberately liberal, no overall SIRwas
signiﬁcantly elevated upon inclusion of these additional
cases. The SIR for patients from the USA was only
elevated for the level 2 sensitivity analysis (possible
cases). Because such unconﬁrmed cases will not be
recorded in the comparator registries and the SIR
increase was small and only for patients from the USA,
we believe that this result is not clinically signiﬁcant and
unlikely to indicate a true increased risk of primary
malignancy in the HypoCCS USA cohort.
There were a number of limitations of this analysis,
particularly the time of follow-up in HypoCCS (mean
3.7 years), which is relatively short but, at least in part,
limited by the time since approval of the adult GHD
indication. Similar analysis with longer follow-up is
needed to conﬁrm assurance of no increase in cancer
risk during GH therapy in adults. In addition, the
general population may not be an ideal comparison
group due to differences in the health proﬁle versus the
GH-deﬁcient population. However, our results are
reassuring since no increase relative to the general
population was found, and GHD patients are unlikely to
be healthier than the general population. Our study
covered the period 1996–2008 but did not take into
account changes in clinical practice during that period.
The etiologies of GHD in the overall cohort changed
during the course of HypoCCS, with a relative decrease
in the proportion of intracranial tumors and pituitary
dysfunction diagnoses (22). In comparison of SIRs for
GH-treated and non GH-treated patients, those treated
with GH were relatively younger and had a higher rate
of idiopathic GHD diagnosis (Table 1), which may
inﬂuence the risk for primary cancers; additionally, the
size of the non GH-treated group was much smaller
than the GH-treated group. Cancer cases were included
in the analysis without considering induction time;
cases diagnosed soon after GH initiation for GH naive
patients in HypoCCS were unlikelydue to GH treatment,
leading to overestimation of observed cases. In addition,
follow-up time was only during HypoCCS, and a patient
treated with GH prior to HypoCCS would have had extra
time not added to the patient-years calculation.
However, we attempted to address this potential bias
by calculating SIR for patients who were believed to be
GH naive at HypoCCS entry, which was found to be
similar to the overall SIR.
In conclusion, the incidence of primary cancer in
patients with GHD enrolled in HypoCCS who were
treated with GH as adults appears similar to that of the
general population. However, such surveillance should
be continued to provide a thorough assessment of
cancer risk during longer follow-up, for speciﬁc tumors
and patients in speciﬁc risk groups.
Declaration of interest
C J Child, A G Zimmermann, J J Li and H Jung are employees and
stockholders of Eli Lilly and Company (Indianapolis, IN, USA). E M
Erfurth, L L Robison and W W Woodmansee are members of Medical
Research advisory boards and have received consulting fees from Eli
Lilly and Company. W W Woodmansee is also a former employee and
stockholder of Eli Lilly and Company. D M Green had no competing
interest or ﬁnancial disclosures to report.
Funding
HypoCCS is sponsored by Eli Lilly and Company (Indianapolis, IN,
USA).
Acknowledgements
The authors gratefully thank all participating investigators and
patients. Additionally, the authors would like to thank Dr Peter Bates
(CambridgeMedicalWritingServices,UK)forhiseditorialreviewofthe
manuscript, and Qi Rong (inVentiv Clinical Solutions, Indianapolis,
USA) for assistance with statistical programing and analysis.
HypoCCS Advisory Board Membership of the HypoCCS
Advisory Board as of February 2011 was Andrea FAttanasio (Agliano
Terme, Italy), Paolo Beck-Peccoz (Milan, Italy), Werner F Blum (Bad
Homburg, Germany), Roger Bouillon (Leuven, Belgium), Philippe
Chanson (Le Kremlin-Bice ˆtre, France), Kazuo Chihara (Kakogawa,
Japan), David R Clemmons (Chapel Hill, USA), Eva Marie Erfurth
(Lund, Sweden), Mark Hartman, (Indianapolis, USA), Ken Y Ho
(Brisbane, Australia), Heike Jung (Bad Homburg, Germany), David L
Kleinberg (New York, USA), Steven W J Lamberts (Rotterdam,
Netherlands), Shlomo Melmed (Los Angeles, USA), Richard J Ross
(Shefﬁeld, United Kingdom), Les L Robison (Memphis, USA), Akira
Shimatsu (Kyoto, Japan), Christian J Strasburger (Berlin, Germany),
Susan M Webb (Barcelona, Spain), Whitney W Woodmansee (Boston,
USA), and Alan G Zimmermann (Indianapolis, USA).
Table 5 Primary colorectal cancer incidence in all GH-treated and
non GH-treated patients and in GH-treated patients by gender.
SIRs were calculated using SEER data (24) for cases from the USA
(nZ6, GH-treated and nZ5, non GH-treated), and GLOBOCAN





cases SIR (95% CI)
GH-treated (nZ6840) 11 18.18 0.60 (0.30–1.08)
Non GH-treated (nZ940) 5 3.31 1.51 (0.49–3.52)
GH-treated males (nZ3571) 9 12.28 0.73 (0.34–1.39)
GH-treated females (nZ3269) 2 5.91 0.34 (0.04–1.22)
CI, conﬁdence interval; SIR, standardized incidence ratio.
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